|A first of its kind, the NYU Langone Center for Psychedelic Medicine will advance a burgeoning area of basic science by providing a dedicated, essential infrastructure for research and training in therapeutic use of psychedelics.|
The new center builds on long-standing expertise at NYU Langone Health that garnered more than $10 million in donations for its creation. Researchers at NYU Langone have published seminal papers on the clinical benefits of psychedelics to treat a range of conditions, including addiction, cancer-related psychiatric conditions, major depression, and post-traumatic stress disorder.
The center boasts more than 30 dedicated researchers and is currently enrolling in five clinical trials. For early career scientists, the center offers the nation’s first Psychedelic Medicine Research Training Program.
“These initiatives will provide an environment in which scientists, clinicians, trainees, and other staff contribute in meaningful ways to ensure that the momentum created by the modern psychedelic renaissance is sustained and continue to yield medical breakthroughs backed by sound science,” says center director Michael P. Bogenschutz, MD, a professor of psychiatry.
For more information, visit the NYU Langone Center for Psychedelic Medicine.